*Refresh the page if the below document does not appear.
In light of the two unfortunate incidents that happened during the last month, which includes death of Gambian children due to substandard drugs and death of five people in Chandigarh, the public confidence in Indian drugs might get reduced and the industry as a whole might have to suffer losses.
The Hyderabad-based private firm stated that they are actively considering the fact of separating their non-vaccine business and selling the equity stakes to investors to raise required funds. Furthermore, the Managing Director said that they want to make this decision sooner than later.
On Wednesday, the leading pharmaceutical company announced that its product Evrysdi (risdiplam), indicated for the treatment of the genetic disorder, Spinal Muscular Atrophy (SMA), has shown encouraging outcomes. The results came from the fresh two-year-old data from the largest ever “Jewelfish” study.
After the issuance of the show-cause notice on October 7, the state drug control authority gave the company a week’s time to revert. The use of toxic solvent, contaminated solvents without conducting proper tests, and discrepancies in manufacturing dates are among the 12 faults that were found to support the ban decision.
US FDA announced the unavailability of the drug through a website posting. The drug makers informed the regulatory authority that the manufacturing and supply delays might last through March next year. The drug is used for the treatment of attention deficit hyperactivity disorder and narcolepsy.
The interpretation of the data revealed GSK’s respiratory syncytial virus (RSV) vaccine to be 82.6% effective in a cautiously watched latestage study involving old aged adults. The company’s chief scientific officer stated that these are very promising results as RSV is still one of the major infectious diseases without any vaccine available.
The therapeutics company’s experimental
treatment for major depressive disorder failed to
give promising results in a highly anticipated
late-stage trial. The drug failed to show
statistically significant improvement in the
symptoms of depression in patient subjects
when compared to a placebo.